Melanotan-2

Dr. Portela notes the Swedish Poisons Information Center has tracked Melanotan 2 adverse events since 2008 and logged 215 cases of people calling in about side effects over just over a decade. He frames this as a single country's tally that almost certainly dramatically undercounts actual use and side-effect incidence.

Dr. Portela describes case reports of renal infarction in MT-2 users, essentially a stroke of the kidney where blood supply is cut off. He attributes the mechanism to vasoconstriction from sympathetic nervous system overstimulation narrowing the vessels feeding the kidney, calls it potentially life-threatening, and notes it is often misdiagnosed initially because it is so rare.

Dr. Portela recounts a case of a 39-year-old man who injected 6mg of MT-2 bought online, roughly six times the recommended starting dose, and presented to the ER two hours later with body aches, sweating and tachycardia peaking near 146 bpm. His CPK (a marker of muscle breakdown) rose from 1,760 to over 17,000 against a normal range under 200, consistent with rhabdomyolysis that can cause acute kidney failure. He survived after three days in the ICU. Portela attributes the overdose to dosing guidance coming from internet forums rather than a prescribing physician.

Dr. Portela describes priapism as a documented MT-2 medical emergency. A 55-year-old man who had used MT-2 for six years without incident injected just 2mg and developed a sustained painful erection that lasted 30 hours by ER arrival, failing cavernosal aspiration and phenylephrine before requiring surgery. A separate British Medical Journal case report titled 'Melanotan-induced priapism: a hard-earned tan' involved a patient who avoided surgery after a 20-plus hour erection but had still not regained erectile function at four-week follow-up.

Dr. Portela cites dermatology case reports of rapid, concerning nevus changes in MT-2 users: a 25-year-old man with multiple new moles and rapid transformation of existing moles within weeks; a 24-year-old bodybuilder with eruption of new moles and darkening of existing ones within 24 hours of a single injection; a 19-year-old with eruptive nevi alongside tanning bed use; and 30- and 48-year-old women whose pre-existing moles became severely dysplastic. He stresses darkening, enlarging or new moles are a sign of the drug working and warrant immediate dermatologist evaluation.

Dr. Portela cites a 2025 case report of a 22-year-old woman using the nasal spray form of Melanotan 2 who developed a mass in her anterior maxilla, biopsy-confirmed as mucosal malignant melanoma, requiring surgical resection and ongoing immunotherapy. He notes this is the first reported case involving the nasal spray formulation and the first mucosal melanoma potentially linked to MT-2, arguing the route of administration may not limit risk the way some users assume.

Dr. Portela walks through published melanoma case reports tied to MT-2: a 20-year-old fair-skinned (Fitzpatrick type II) woman diagnosed with melanoma after a 3-4 week course plus tanning bed use; a 42-year-old woman with years of clear skin checks who grew a 0.3mm melanoma within three months of a one-week course; and a 23-year-old red-haired woman who developed three synchronous melanomas after three years and was later found to carry MC1R and CDKN2A (tumor suppressor) mutations she never knew about. He frames MT-2 as directly stimulating melanocytes, the exact cells that become melanoma.

Dr. Portela explains the FDA moved Melanotan 2 and about 18 other peptides from category 2 (off-limits to compounding pharmacies) into category 1, making them legally recognizable and prescribable so compounding pharmacies can work with them again. He stresses this is not clinical approval for any condition and does not mean the peptides were tested for long-term safety, only that they now sit in a more accessible legal gray zone. Most product sold online is a lyophilized powder labeled 'not for human use', a loophole letting black-market sellers avoid regulation while buyers reconstitute and self-dose with no standardization.

In a sunlight-focused conversation the hosts describe increased libido as a real benefit of the melanocortin pathway triggered downstream of POMC, but characterize MT-2's erectile effect as 'too much' and 'a problem, but it does work.' They note MT-1 has been largely phased out, and that PT-141 (bremelanotide), a downstream melanocortin, can be isolated and taken for libido alone without the pigmentary effects of MT-2.

Peptide Buddy explains PT-141 (bremelanotide) is a metabolite of melanotan-2 and structurally identical except a terminal amine group is replaced with a hydroxy group; both are cyclic peptides derived from alpha-MSH. Melanotan-2 (a truncated cyclic analog of melanotan-1) was pursued for tanning but discontinued due to unpredictable aphrodisiac effects and greater cancer/melanoma concern, while PT-141 was developed for the sexual-arousal market and gained FDA approval as Vyleesi.

A physician reactor debunking peptide misinformation states that Clinuvel halted phase 2 development of Melanotan 2 for cardiovascular side effects (hypertension) and sexual dysfunction (erections that would not stop). He notes there is no documented phase 2 trial fatality for MT-2, contradicting an influencer's claim of a trial death.

This peptide-focused channel contrasts the two: MT-1 (afamelanotide, branded Scenesse) is FDA-approved for erythropoietic protoporphyria, works predominantly through MC1R, preferentially boosts UV-absorbing eumelanin over carcinogenic pheomelanin, and has a favorable safety profile with no evidence at this point of increased melanoma risk. MT-2 is a shortened cyclic analog with broader affinity for MC3, MC4 and MC5, which is why users report libido and appetite effects alongside tanning, and it is that broad affinity plus multiple case reports of melanocytic changes and melanomas that make it the higher-risk cousin.

Dr. Portela is careful to say causality has not been definitively proven: a 2013 review found no conclusive evidence MT-2 directly causes melanoma, and a 2021 review noted the elevated risk could partly reflect that users also pursue aggressive UV and tanning bed exposure, with reported cases carrying additional risk factors like fair skin and family history. He counters that MT-2 powerfully stimulates melanocytes, and as one researcher put it, stimulating pigment cells enough can cause abnormal proliferation, the way melanoma starts, describing it as pouring gasoline on a fire that may already exist.

Dr. Portela describes the near-guaranteed MT-2 side effect profile as nausea, stomach cramps, facial flushing, fatigue and decreased appetite, with most users experiencing at least several. In men, spontaneous erections within 1 to 5 hours of injection are described as a known documented pharmacological effect of MC4 activation baked into the drug's mechanism, not a rare event. He also notes a central-nervous-system 'yawning and stretching complex' that signals the compound does far more than tan the skin.

Dermatologist Dr. Dustin Portela explains Melanotan 2 is a synthetic peptide mimicking alpha-melanocyte stimulating hormone (alpha-MSH). Unlike the body's natural signal it is not selective: MC1 activation produces the tan people want, while MC4 activation drives flushing, nausea and spontaneous erections, and MC3 affects appetite suppression and GI symptoms. Because it crosses the blood-brain barrier it also acts on the central nervous system, appetite regulation, sexual function and cardiovascular response.